Evidence map›Paper›PMID 37234386›Full record

ArticleFujita medical journal2023

Combination of brain natriuretic peptide and urinary albumin as a predictor of cardiovascular-renal events in outpatients with chronic kidney disease.

Shoya Oyama, Hiroshi Takahashi, Hiroki Hayashi, Shigehisa Koide, Shigeru Nakai, Kazuo Takahashi, Daijo Inaguma, Midori Hasegawa, Junichi Ishii, Yukio Yuzawa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fujita medical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shoya OyamaDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Hiroshi TakahashiDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Hiroki HayashiDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Shigehisa KoideDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Shigeru NakaiFaculty of Clinical Engineering, Fujita Health University, School of Medical Sciences, Toyoake, Aichi, Japan.
Kazuo TakahashiDepartment of Biomedical Molecular Sciences, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Daijo InagumaDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Midori HasegawaDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Junichi IshiiDepartment of Cardiovascular Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Yukio YuzawaDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Naotake TsuboiDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Cardiovascular and renal diseases are closely related. Brain natriuretic peptide (BNP) and urinary albumin are established predictors for cardiac and renal morbidities, respectively. To date, no reports have investigated the combined predictive value of BNP and urinary albumin for long-term cardiovascular-renal events in patients with chronic kidney disease (CKD). The aim of this study was to investigate this theme. Methods: Four hundred eighty-three patients with CKD were enrolled into this study and followed-up for 10 years. The endpoint was cardiovascular-renal events. Results: During the median follow-up period of 109 months, 221 patients developed cardiovascular-renal events. Log-transformed BNP and urinary albumin were identified as independent predictors for cardiovascular-renal events, with a hazard ratio of 2.59 (95% confidence interval [CI], 1.81-3.72) and 2.27 (95% CI, 1.82-2.84) for BNP and urinary albumin, respectively. For the combined variables, the group with high BNP and urinary albumin had a markedly higher risk (12.41-times; 95% CI 5.23-29.42) of cardiovascular-renal events compared with that of the group with low BNP and urinary albumin. Adding both variables to a predictive model with basic risk factors improved the C-index (0.767, 0.728 to 0.814, p=0.009), net reclassification improvement (0.497, p<0.0001), and integrated discrimination improvement (0.071, p<0.0001) more than each of them alone. Conclusions: This is the first report to demonstrate that the combination of BNP and urinary albumin can stratify and improve the predictability of long-term cardiovascular-renal events in CKD patients.

Indexed as

Brain natriuretic peptideCardiovascular–renal eventsChronic kidney diseaseUrinary albumin

Identifiers

PMID37234386
PMCPMC10206898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.